Clinical Trial

A Single-arm, Multi-center, Phase II Exploratory Clinical Study to Evaluate the Efficacy and Safety of Trilaciclib in Preventing Myelosuppression Caused by Topoisomerase I Inhibitor Type ADC Drugs

Name: A Single-arm, Multi-center, Phase II Exploratory Clinical Study to Evaluate the Efficacy and Safety of Trilaciclib in Preventing Myelosuppression Caused by Topoisomerase I Inhibitor Type ADC Drugs — clinical trial record (NCT07736001)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: Trilaciclib

Not Yet Recruiting

View on ClinicalTrials.gov →

Summary

Evaluation of the efficacy and safety of Trilaciclib in preventing myelosuppression caused by topoisomerase I inhibitor type ADC drugs

Trial Details

NCT Number	NCT07736001
Lead Sponsor	Tianjin Medical University Cancer Institute and Hospital
Conditions	Tumor Patients
Enrollment	96 participants
Start Date	2026-07
Primary Completion	2029-07 (estimated)
Study Completion	2029-07 (estimated)
Updated on ClinicalTrials.gov	2026-07-30